Neoplasms

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Rare Diseases

Neoplasm Metastasis

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Apatinib

Oxaliplatin

Protein Kinase Inhibitors

Enzyme Inhibitors

Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited

three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.

Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).

Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.

Apatinib plus XELOX

Zhaoqing Tang, MD

Yi-Hong Sun, MD

Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer PatientsWith lymph node metastasis

This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With lymph node metastasis

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis

Both CR and PR according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

The safety of the the perioperative treatment, percentage of grade 3 or 4 adverse events as safety profile of perioperative treatments

Briefly, pathCR (Pathological complete rate) was defined as an absence of carcinoma cells in the primary site, and pathologic partial response (pathPR) was defined as less than 10% residual carcinoma cells in the specimen.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer	NCT03229096	Chemotherapy Ef... Chemotherapeuti... Gastric Cancer	Apatinib plus X...	18 Years - 75 Years	Shanghai Zhongshan Hospital
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer	NCT03229096	Chemotherapy Ef... Chemotherapeuti... Gastric Cancer	Apatinib plus X...	18 Years - 75 Years	Shanghai Zhongshan Hospital

Spots Global Cancer Trial Database for apatinib plus xelox